Round 2 in Boehringer's US re­or­ga­ni­za­tion will claim an­oth­er 244 jobs, in­clud­ing small mol­e­cule group

Boehringer In­gel­heim is once again tak­ing out its bud­get ax and hack­ing away jobs. Five months af­ter the com­pa­ny told me that it was chop­ping 725 jobs out of its US struc­ture, the Ger­man phar­ma com­pa­ny is hack­ing out an­oth­er 244 po­si­tions, in­clud­ing 120 in­volved in small mol­e­cule dis­cov­ery re­search in Con­necti­cut and bring­ing the to­tal to close to a thou­sand.

The rest of the cuts in­clud­ed 60 staffers in var­i­ous func­tions with an­oth­er 64 sales jobs be­ing elim­i­nat­ed as well.

And just like last June, Boehringer styled these new cuts as a way for them to do their job in drug de­vel­op­ment even bet­ter, with few­er peo­ple.

As a com­pa­ny, Boehringer has no trou­ble draw­ing the cur­tains when it’s mak­ing changes. That tac­tic was em­ployed just two months ago, when Boehringer an­nounced that it was drop­ping a pact with South Ko­rea’s Han­mi on the can­cer drug ol­mu­tinib, with­out men­tion­ing that the drug had been linked to se­vere tox­i­c­i­ty. Ko­re­an of­fi­cials had cit­ed at least one death and two se­vere ad­verse events in stud­ies of the drug. An­oth­er re­port cit­ed by the po­lit­i­cal op­po­si­tion said three pa­tients had died.

Ru­mors about the lat­est lay­offs were cir­cu­lat­ing this morn­ing, and the news was first re­port­ed by In The Pipeline’s Derek Lowe.

Here’s the state­ment:

The ac­tions we are tak­ing now will help us rein­vent the way we serve the needs of our pa­tients, and en­able us to con­tin­ue to iden­ti­fy new med­ical break­throughs.

In or­der to con­tin­ue to de­liv­er on our re­search strat­e­gy, we must cre­ate a lean­er glob­al Dis­cov­ery Re­search or­ga­ni­za­tion by con­sol­i­dat­ing small mol­e­cule dis­cov­ery to two sites in Bib­er­ach, Ger­many and Vi­en­na, Aus­tria. This de­ci­sion will re­sult in the clo­sure of the small mol­e­cule dis­cov­ery func­tions in Ridge­field, CT and Mi­lan, Italy.

The cre­ation of a lean­er glob­al Dis­cov­ery Re­search or­ga­ni­za­tion will al­low for in­creased in­vest­ments in On­col­o­gy, with a fo­cus on can­cer im­munol­o­gy. The abil­i­ty to mod­u­late the body’s own im­mune sys­tem has opened new ex­cit­ing ways to treat can­cer. A new group will be formed, and led out of Ridge­field be­gin­ning in 2017 that will fo­cus on can­cer im­munol­o­gy dis­cov­ery re­search. This new group will re­sult in ap­prox­i­mate­ly 35 new po­si­tions in Con­necti­cut.

Am­gen lays off about 300 work­ers, cit­ing 'in­dus­try head­wind­s'

Amgen has laid off about 300 employees, a company spokesperson confirmed to Endpoints News via email Sunday night.

Employees posted to LinkedIn in recent days about layoffs hitting Amgen last week. The Thousand Oaks, CA-based biopharma, which employs about 24,000 people, said the reduction “mainly” impacted US-based workers on its commercial team.

Drug developers of all sizes, including small upstarts and pharma giants, have let employees go in recent months as the biopharma market drags through a quarters-long winter doldrum.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Bob Bradway, Amgen CEO (Stephen Lam/Reuters)

Am­gen launch­es the first US Hu­mi­ra biosim­i­lar at two dif­fer­ent list prices

The bizarre dynamics of the US prescription drug market were on full display once again this morning as Amgen announced that it would launch the first US biosimilar for Humira, the best-selling drug of all time, at two completely different list prices.

One price for Amgen’s Amjevita (adalimumab-atto) will be 55% below the current Humira list price, which is about $84,000 per year, and another at a list price 5% below the current Humira list price, but presumably (pharma companies don’t disclose rebates) with high rebates to attract PBMs and payers.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 157,800+ biopharma pros reading Endpoints daily — and it's free.

Boehringer In­gel­heim touts pre­ven­tion re­sults in rarest form of pso­ri­a­sis

Boehringer Ingelheim uncorked some positive results suggesting that Spevigo can help prevent flare-ups in patients with a severe form of psoriasis, months after the drug was approved to treat existing flares.

Spevigo, an IL-36R antibody also known as spesolimab, met its primary and a key secondary endpoint in the Phase IIb EFFISAYIL 2 trial in patients with generalized pustular psoriasis (GPP), Boehringer announced on Monday. While the company is keeping the hard numbers under wraps until later this year, it said in a news release that it anticipates sharing the results with regulators.

Credit: Shutterstock

New York City in­vests $20M in­to biotech 'in­no­va­tion space' at the Brook­lyn Navy Yard

New York City is investing $20 million in biotech this year in the form of a 50,000-square-foot “innovation space” at the Brooklyn Navy Yard, complete with offices, research laboratories and events and programming space to grow biotech startups and companies.

Mayor Eric Adams said during his State of The City Address last Thursday that there will be an “emphasis” on making more opportunities for women and people of color to further diversify the industry. The City first reported the news.

As­traZeneca, No­vo Nordisk and Sanofi score 340B-re­lat­ed ap­peals court win over HHS

AstraZeneca, Novo Nordisk, and Sanofi won an appeals court win on Monday, as the US Court of Appeals for the Third Circuit found that the companies cannot be forced to provide 340B-discounted drugs purchased by hospitals from an unlimited number of community and specialty pharmacies.

“Legal duties do not spring from silence,” the decision says as the court makes clear that the federal government’s interpretation of the “supposed requirement” that the 340B program compels drugmakers to supply their discounted drugs to an unlimited number of contract pharmacies is not correct, noting:

Ap­peals court toss­es J&J's con­tro­ver­sial 'Texas two-step' bank­rupt­cy case

A US appeals court has ruled against Johnson & Johnson’s use of bankruptcy to deal with mounting talc lawsuits, deciding that doing so would “create a legal blind spot.”

The Third Circuit Court of Appeals reversed a previous bankruptcy court decision on Monday, calling for the dismissal of a Chapter 11 filing by J&J’s subsidiary LTL Management.

Faced with more than 38,000 lawsuits alleging its talc-based products caused cancer, J&J spun its talc liabilities into a separate company called LTL Management back in October 2021 and filed for bankruptcy, a controversial move colloquially referred to as a “Texas two-step” bankruptcy. Claimants argued that the strategy is a misuse of the US bankruptcy code — and on Monday, a panel of judges agreed.

Chad Mirkin, Flashpoint co-founder

‘The field is at a flash­point’: New Chad Mirkin-found­ed biotech hopes to make more ef­fec­tive can­cer vac­cines

Following the success of the mRNA Covid vaccines, cancer vaccines are seeing renewed interest after years of middling results. But a group of researchers suggests that more attention needs to be paid not to what goes into those vaccines, but how the parts are put together.

In a recent paper published in Nature Biomedical Engineering, researchers led by Northwestern University’s Chad Mirkin describe how the placement of different antigens in a cancer vaccine impacts its efficacy. The paper builds on past work done by Mirkin’s lab that suggests the structure, or how the parts of a vaccine are arranged, impact a vaccine’s efficacy, not just its components.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 157,800+ biopharma pros reading Endpoints daily — and it's free.

Dirk Thye, Quince Therapeutics CEO

Af­ter piv­ot­ing from Alzheimer's to bone con­di­tions, biotech piv­ots again — and halves its head­count

When troubled public biotech Cortexyme bought a private startup named Novosteo and handed the keys to its executive team, the company — which changed its name to Quince Therapeutics — said it would shift its focus from an unorthodox Alzheimer’s approach to Novosteo’s bone-targeting drug platform.

Less than a year later, Quince is pivoting again.

The biotech has decided to out-license its bone-targeting drug platform and its lead drug, NOV004, and instead look for clinical-stage programs to in-license or acquire, according to a press release.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 157,800+ biopharma pros reading Endpoints daily — and it's free.

Richard Gonzalez, AbbVie CEO (Chris Kleponis/picture-alliance/dpa/AP Images)

Up­dat­ed: $100B+ in sav­ings? Why the in­com­ing Hu­mi­ra biosim­i­lars will take time to catch on

The 20-year reign of AbbVie’s best-selling biologic of all time — the autoimmune disease biologic Humira (adalimumab) that has brought in upwards of $200 billion during its monopoly — is coming to an end tomorrow with the launch of Amgen’s biosimilar Amjevita.

The launch comes more than four years after Europe saw the exact same competition, leading to steep discounts in price, higher uptake, and big cost savings across the board.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 157,800+ biopharma pros reading Endpoints daily — and it's free.